Leveraging Advanced Screening Platforms

---

Working with our partners, we apply innovative approaches to identify optimized therapeutic leads for treating cancer and osteoarthritis. 

We have access to proprietary next-generation discovery platforms that leverage extensive canine antibody and protein elements, comprising billions of unique therapeutic candidates. These are systematically screened against specific therapeutic targets to identify candidates with optimal binding affinity and functional properties. The resulting leads are then advanced for further testing before entering development. 

In the case of peptide and protein therapeutics, computational biology and advanced protein-engineering are used to convert recombinant proteins into material-binding variants that allow precise, local delivery into an osteoarthritic joint or at a tumor site. This approach allows higher therapeutic concentrations locally with the potential for fewer off-target effects.